Annals of the rheumatic diseases
The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.
1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis.
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs.
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
POS0137 INITIATION OF GLUCOCORTICOIDS BEFORE ENTERING RHEUMATOLOGY CARE ASSOCIATES WITH LONG-TERM GLUCOCORTICOID USE IN ELDERLY PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: A JOINT ANALYSIS OF MEDICARE AND THE RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENES
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES.
POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY.
AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES.
AB1467 EFFECTIVENESS OF TELEMEDICINE IN RHEUMATOLOGY: A MULTI-SITE RANDOMIZED, SINGLE-BLIND, PARALLEL GROUP, NONINFERIORITY TRIAL IN THE UNITED STATES.
